Pluristem Receives Russian Patent For Placenta-Derived Cell Treatment For Inflammatory Bowel Disease

Pluristem Receives Russian Patent For Placenta-Derived Cell Treatment For Inflammatory Bowel Disease
The Israeli-based placenta cell therapies developer Pluristem Therapeutics was recently granted a patent for its study “Methods of Treating Inflammatory Colon Diseases” by Russia’s Federal Service for Intellectual Property, as announced by the company. The patent covers the use of placenta-derived cells in the treatment of ulcerative colitis or Crohn’s disease. For that, the company developed a protein

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *